摘要
为了优选粒径在１００ｎｍ左右、圆整的阿昔洛韦聚氰基丙烯酸正丁酯毫微粒的制备工艺及条件，采用单因素法初选影响阿昔洛韦毫微粒的成粒因素，以毫微粒的形态、药物包封率、毫微粒载药量为综合评价指标，采用均匀设计法精选制备条件和工艺，并用高效液相色谱法测定含药毫微粒中阿昔洛韦的含量。结果：确定了制备条件和工艺，制得的阿昔洛韦毫微粒圆整，算术平均径为１０８．５±９４．８ｎｍ（ｎ＝５８８），载药量为１８．５％，包封率为７１．８％。提示该研究确定的阿昔洛韦毫微粒制备工艺和条件稳定，可用于该毫微粒的制备。
The aim of this study was to optimize the conditions and technology of preparing acyclovirpolybutylcyanoacrylatenanoparticles (ACVPBCANP) which has the diameter of about 100 nm and the shape of a sphere. The influential factors on sphericization were observed by single factor optimization. The preparation conditions and technology were optimized by the even design method. The contents of acyclovirin in acyclovir polybutyloganoacrylate nanoparticles were determined by HPLC. The optimum conditions and technology of preparing acyclovir polybutylcyanoacrylate nanoparticles were decided and put into use. The average diameter of the ACVPBCANP thus prepared was 108.5±94.8 (n=588). Its embedding ratio was 71.8%, and drug loading was 18.5%. The results suggest that the conditions and technology of preparing ACVPBCANP presented in this paper are stable and practical.
出处
《华西医科大学学报》
CSCD
1998年第3期329-333,共5页
Journal of West China University of Medical Sciences
基金
国家自然科学基金
关键词
阿昔洛韦
聚氰基丙烯酸酯
毫微粒
均匀设计法
Acyclovir Polybutylcyanoacrylate nanoparticles HPLC Even design method
